A Database of Drug Repurposing Clinical Trials in Oncology

Pantziarka, Pan; Vandeborne, Liese; Bouche, Gauthier

doi:10.3389/fphar.2021.790952

Cited by 17 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also one of the most popular of the non-cancer drugs being clinically investigated as a possible cancer treatment. The ReDO_Trials Database ( , accessed on 22 November 2021), an online resource that lists active oncology trials investigating the use of non-cancer drugs as anti-cancer agents, lists 131 (16% of the total) active trials that include metformin in an investigation arm (as of 22 November 2021) [ 62 ]. Additionally, there are numerous trials of metformin as a cancer-prevention agent in high-risk populations such as people with familial adenomatous polyposis, oral pre-malignant lesions and those suffering from metabolic syndrome at high risk of developing cancer.…”

Section: Drugging the Undruggablementioning

confidence: 99%

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome

Pantziarka

Blagden

2022

Cancers

Self Cite

View full text Add to dashboard Cite

The concept of the pre-cancerous niche applies the ‘seed and soil’ theory of metastasis to the initial process of carcinogenesis. TP53 is at the nexus of this process and, in the context of Li-Fraumeni Syndrome (LFS), is a key determinant of the conditions in which cancers are formed and progress. Important factors in the creation of the pre-cancerous niche include disrupted tissue homeostasis, cellular metabolism and chronic inflammation. While druggability of TP53 remains a challenge, there is evidence that drug re-purposing may be able to address aspects of pre-cancerous niche formation and thereby reduce the risk of cancer in individuals with LFS.

show abstract

Section: Drugging the Undruggablementioning

confidence: 99%

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome

Pantziarka

Blagden

2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…This strategy searches for new medical applications for already approved or investigational drugs in another indications. This approach is particularly advantageous due to the existing information on the safety profile of already registered drugs and can significantly reduce development costs and timelines [ 2 , 3 ]. Drugs from the salicylanilide group, resulting from the coupling of a salicylic acid and an aniline, are one of the promising candidates for repurposing in oncology.…”

Section: Introductionmentioning

confidence: 99%

Salicylanilides and Their Anticancer Properties

Kauerova

Pérez‐Pérez

Kollár

2023

IJMS

View full text Add to dashboard Cite

Salicylanilides are pharmacologically active compounds with a wide spectrum of biological effects. Halogenated salicylanilides, which have been used for decades in human and veterinary medicine as anthelmintics, have recently emerged as candidates for drug repurposing in oncology. The most prominent example of salicylanilide anthelmintic, that is intensively studied for its potential anticancer properties, is niclosamide. Nevertheless, recent studies have discovered extensive anticancer potential in a number of other salicylanilides. This potential of their anticancer action is mediated most likely by diverse mechanisms of action such as uncoupling of oxidative phosphorylation, inhibition of protein tyrosine kinase epidermal growth factor receptor, modulation of different signaling pathways as Wnt/β-catenin, mTORC1, STAT3, NF-κB and Notch signaling pathways or induction of B-Raf V600E inhibition. Here we provide a comprehensive overview of the current knowledge about the proposed mechanisms of action of anticancer activity of salicylanilides based on preclinical in vitro and in vivo studies, or structural requirements for such an activity.

show abstract

“…These repurposing drugs include molecules that are already in use but also molecules that are shelved, abandoned, or withdrawn due to their unexpected off-target performance, as well as their primary designated performance is not as expected [ 8 ]. A previous study elicited by Pantziarka et al established a drug repurposing database, namely ReDO_DB, which is a curated list of original non-cancer drugs with demonstrated evidence of anti-cancer activity by using the data from peer-reviewed research reports, medical case reports, observational studies, and clinical trials [ 9 , 10 ]. They found that as of August 2021, there were 356 candidate drugs from ReDO_DB that showed potential anti-cancer activity.…”

Section: Introductionmentioning

confidence: 99%

“…They found that as of August 2021, there were 356 candidate drugs from ReDO_DB that showed potential anti-cancer activity. Among these 356 repurposing drugs, 164 have been involved in clinical trials of anti-cancer studies [ 10 ]. These impressive research projects on drug repurposing provide hope for the treatment of cancer and also provide clues for some of the unmet needs for cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

Drug Repurposing: The Mechanisms and Signaling Pathways of Anti-Cancer Effects of Anesthetics

Liao

Yeh

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Cancer is one of the leading causes of death worldwide. There are only limited treatment strategies that can be applied to treat cancer, including surgical resection, chemotherapy, and radiotherapy, but these have only limited effectiveness. Developing a new drug for cancer therapy is protracted, costly, and inefficient. Recently, drug repurposing has become a rising research field to provide new meaning for an old drug. By searching a drug repurposing database ReDO_DB, a brief list of anesthetic/sedative drugs, such as haloperidol, ketamine, lidocaine, midazolam, propofol, and valproic acid, are shown to possess anti-cancer properties. Therefore, in the current review, we will provide a general overview of the anti-cancer mechanisms of these anesthetic/sedative drugs and explore the potential underlying signaling pathways and clinical application of these drugs applied individually or in combination with other anti-cancer agents.

show abstract

A Database of Drug Repurposing Clinical Trials in Oncology

Cited by 17 publications

References 14 publications

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome

Salicylanilides and Their Anticancer Properties

Drug Repurposing: The Mechanisms and Signaling Pathways of Anti-Cancer Effects of Anesthetics

Contact Info

Product

Resources

About